clinical trial · NCT05605899
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Kite, A Gilead Company·phase3·active not recruiting·n = 300
High-risk Large B-cell Lymphoma (LBCL)Axicabtagene CiloleucelCyclophosphamideFludarabineEtoposideRituximabDoxorubicinVincristinePrednisone
brief summary
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
started
Feb 10, 2023
primary completion
Mar 1, 2031
completion
Mar 1, 2031
last updated
Apr 15, 2026
detailed description
Five years after randomization, participants who have received axicabtagene ciloleucel will transition to a separate long-term follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.
official title
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol